EZH2
EZH2 is a histone methyltransferase involved in epigenetic regulation. Gain-of-function mutations are implicated in certain lymphomas and are targets for epigenetic therapies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where EZH2 is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Follicular Lymphoma Tumor Heme · Lymphoma |
|
Approvals defined at the solid tumor level where EZH2 is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report EZH2 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports EZH2 as part of its biomarker panel.